In the ClarIDHy phase III trial, patients with isocitrate dehydrogenase (IDH1)-mutated CCA who progressed on previous therapies responded considerably to ivosidenib in terms of both progression-free survival (PFS) and OS [10]. Here, IDH1 is linked to cholangiocarcinoma.